Stomach acid drugs may increase vitamin
deficiency risk
Popular
drugs that are used to control stomach acid may increase the risk of a serious
vitamin deficiency, suggests a new study.
Researchers
found people who were diagnosed with vitamin B12 deficiency were more likely to
be taking proton-pump inhibitors (PPIs) and histamine 2 receptor antagonists
(H2RAs), compared to those not diagnosed with the condition.
The
drugs are commonly used to treat conditions like acid reflux - also known as
GERD - and peptic ulcers.
"This
doesn't mean people should stop their medications," Dr. Douglas Corley,
the study's senior author, said. "People take these for good reasons. They
improve quality of life and prevent disease."
"It
does raise the question that people who are taking these medications should
have their B12 levels checked," he added.
Corley,
a gastroenterologist, is a researcher at the Kaiser Permanente Division of
Research in Oakland, California.
Humans
typically get vitamin B12 from eating animal products. B12 is also added to
many processed foods and can also be purchased as a supplement.
Without
enough vitamin B12, people become tired, weak, constipated and anemic,
according to the U.S. National Institutes of Health. Ultimately, the vitamin
deficiency can lead to nerve damage and dementia.
The
problem is that the body absorbs B12 with the help of stomach acid. Because
PPIs and H2RAs limit the stomach's production of acid - and the body needs
stomach acid to absorb B12 - the drugs could "theoretically increase the
population's risk of vitamin B12 deficiency," the researchers write in the
Journal of the American Medical Association (JAMA).
Commonly
used PPIs include omeprazole (also known as Prilosec), esomeprazole (sold as
Nexium), and lansoprazole (Prevacid). H2RAs include cimetidine (Tagamet),
famotidine (Pepcid), and ranitidine (Zantac).
For
the new study, the researchers compared the medical records of nearly 26,000
Northern California residents who were diagnosed with a vitamin B12 deficiency
between 1997 and 2011, and nearly 185,000 people with healthy B12 levels.
Among
those who were vitamin B12 deficient, 12 percent had been on PPIs for at least
two years and about 4 percent were on H2RAs for an equally long period.
By
comparison, among people without a diagnosis of B12 deficiency, 7 percent had
been on PPIs for two or more years and 3 percent were on H2RAs long-term.
Not
only were PPIs and H2RAs tied to an increased risk of vitamin B12 deficiency,
but higher doses were more strongly associated with deficiency than weaker
ones, the researchers found.
Those
findings, Corley said, suggests that people should use the drugs for as short a
time as possible, and take the lowest dose that's still effective.
While
the study can't prove that PPIs or H2RAs caused vitamin B12 deficiency, this
isn't the first study to link anti-acid drugs to complications.
Previous
research has tied PPIs to the diarrhea-causing bacteria Clostridium difficile.
"I
think the study is interesting because we're becoming more and more aware that
these drugs are being too widely prescribed," Dr. Peter Green said.
Green,
who was not involved with the new study, is a professor of medicine and
director of the Celiac Disease Center at Columbia University Medical Center in
New York.
In
2012, 14.9 million people in the U.S. received 157 million prescriptions for
PPIs, according to the researchers.
"I
think it's just another little piece of evidence that physicians should take
notice of to get patients off them," Green said.
He
said lifestyle changes may be an alternative treatment along with a switch to
H2RAs, which are less potent and were not as strongly linked to vitamin B12 deficiency.
Corley
said patients can ask their doctor if they should be on these drugs, whether
they need to be on such a strong dose and if they should be screened for
vitamin B12 deficiency.
"It
is a cause for concern, but it's not an emergency for the average person,"
he said. "People shouldn't stop their medication based on this study
alone."

No comments:
Post a Comment